Management Q&A: View from the Top

Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs

Managment Q&A: View from the Top
Source: The Life Sciences Report  (08/17/2016)
Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. read more >

The ASX: Investing in an Emerging Biotech Frontier

Contributed Opinion
Source: Stuart Roberts for The Life Sciences Report  (08/10/2016)
The ASX: Investing in an Emerging Biotech Frontier
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. read more >

Resverlogix Seeks Orphan Status for Lead Drug Candidate

Source: The Life Sciences Report  (08/03/2016)
Resverlogix Seeks Orphan Status for Lead Drug Candidate
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications. read more >

Nobilis Moves Forward with New President and New Canaccord Coverage

Source: The Life Sciences Report  (07/20/2016)
Nobilis Moves Forward with New President and New Canaccord Coverage
Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy. read more >

DURECT's Abuse-Deterrent Opioid Poised for FDA Approval

Source: Tracy Salcedo of The Life Sciences Report  (07/13/2016)
DURECT's Abuse-Deterrent Opioid Poised for FDA Approval
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative. read more >

How Sick Will Brexit Make Biotech and Pharma?

Source: Tracy Salcedo of The Life Sciences Report  (06/29/2016)
How Sick Will Brexit Make Biotech and Pharma?
Given the uncertainty and dire economic forecasts following the Brexit vote, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. read more >

Partnerships Propel Stellar Biotechnologies' Vaccine Technology

Source: Tracy Salcedo of The Life Sciences Report  (06/22/2016)
Partnerships Propel Stellar Biotechnologies' Vaccine Technology
Maxim analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc. With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore. read more >
Expert Investing Ideas
NASDAQ Biotech ARCA Pharmaceutical

Soligenix Develops Defenses Against Bioterrorism

Source: Staff of The Life Sciences Report  (06/15/2016)
Soligenix Develops Defenses Against Bioterrorism
Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company. read more >

Investment in Cell and Gene Therapies Ramps Up

Source: George S. Mack of The Life Sciences Report  (06/08/2016)
Investment in Cell and Gene Therapies Ramps Up
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. read more >
Management Q&A: View from the Top

OncoSec Delivers Cancer Therapy Straight to the Tumor

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (06/01/2016)
OncoSec Delivers Cancer Therapy Straight to the Tumor
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is using a proprietary platform to deliver therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies. read more >
Management Q&A: View from the Top

How Nobilis Health Will Break Out of the Healthcare Payment Mold

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report   (05/25/2016)
How Nobilis Health Will Break Out of the Healthcare Payment Mold
Managing both acquisitions and internal growth at the same time is difficult for most small companies, but not for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. read more >
Biotech Watchlist 2016